High-Dose Melatonin: What the Evidence Actually Shows

Key points

• The meta-analyses we opened found modest effects: about 7 minutes faster sleep onset in primary sleep disorders, and about 23 minutes in delayed sleep phase disorder [1][4].
• No standard definition of “high-dose” exists. The one systematic review that compared dose ranges for jet lag found doses above 5 mg no more effective than lower ones [2].
• US supplements are sold as dietary supplements, and two analyses found measured melatonin far from the label [11][12]. In the UK and EU, melatonin is a prescription medicine [15][16].
• Safety data are reassuring for short trials, thin for long-term use, and an unreviewed 2025 observational heart-failure signal is disputed [7][13][14].
• Verdict on the S-tier ranking: not supported as a cognitive enhancer, and not supported for “high-dose”. Evidence is for sleep timing, not cognition.

What the claim is

On 2026-10-20 the account @dex7official posted a tier list titled “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” [18]. Our team transcribed the list from the image; “high-dose melatonin” sits in tier S, next to “circadian rhythm”. The post cites no evidence and gives no dose. Below we test what the literature says about larger doses.

What “high-dose” means in the literature

Papers do not agree on a threshold. Examples from the sources we opened:

• A 1996 study in 12 healthy young volunteers compared 0.3 mg and 1.0 mg with placebo; both shortened sleep onset, and 0.3 mg raised blood levels to the normal night-time range [5].
• A systematic review of adverse events pooled 37 randomized trials with daily doses from 0.15 mg to 12 mg [7].
• The UK licensed 3 mg tablet for jet lag and the EU 2 mg prolonged-release tablet are the regulated reference points [15][17].
• A 2006 study in ALS followed 31 patients on rectal melatonin at 300 mg for up to two years as a tolerability study, alongside cell and mouse work [6]. It was not a sleep trial and not a test of cognition.

So “high-dose” has no fixed meaning here; the sleep trials we opened sit between 0.15 and 12 mg [5][7]. We did not find a trial of cognitive enhancement in healthy adults among the sources we opened; we did not run a dedicated search for one, so treat that as a gap, not proof of absence.

What the evidence shows

Source	Design	Size	Main finding
Ferracioli-Oda 2013 [1]	Meta-analysis, adults and children with primary sleep disorders	19 trials, 1,683 people	Sleep latency 7.06 min shorter (95% CI 4.37 to 9.75); total sleep time 8.25 min longer (1.74 to 14.75); sleep quality SMD 0.22
Herxheimer and Petrie, Cochrane 2002 [2]	Systematic review, jet lag	10 trials (9 usable)	9 of 10 found less jet lag after flights over 5 or more time zones; authors state NNT of 2
van Geijlswijk 2010 [4]	Meta-analysis, delayed sleep phase disorder	5 adult trials (91 people), 4 child trials (226)	Sleep onset advanced 0.67 h (0.45 to 0.89); latency 23.27 min shorter (4.83 to 41.72); total sleep time unchanged
Auld 2017 [3]	Meta-analysis, primary adult sleep disorders	12 randomized trials from 5,030 records	Most convincing for sleep-onset latency in insomnia and delayed sleep phase; authors call for larger trials

The effect on sleep onset in primary sleep disorders is small. The authors of [1] describe it as modest and smaller than other drugs for insomnia. The delayed sleep phase and jet lag results are the strongest, because there melatonin acts as a timing signal, not a sedative. The jet lag review dates from 2002.

What trials of larger doses found

The dose evidence is weaker than the headline numbers suggest.

• The meta-regression in [1] found that trials using higher doses and longer durations showed larger effects on sleep latency and total sleep time. Meta-regression compares trials with each other, not people randomized to different doses, so it cannot prove that more melatonin works better. It found no dose effect on sleep quality.
• The Cochrane jet lag review reported that doses between 0.5 and 5 mg were similarly effective, that people fell asleep faster after 5 mg than 0.5 mg, and that doses above 5 mg appeared no more effective [2]. It also noted that a 2 mg slow-release form worked less well than immediate release.
• The dose comparison in [5] was 0.3 versus 1.0 mg in healthy sleepers, far from a large-dose design.
• The 300 mg ALS work [6] reports tolerability in 31 people for up to two years; it does not address sleep or cognition and was exploratory.

The quality caveat applies across the board. In the 37-trial safety review, only 8 trials rated “good” on risk of bias, 16 “fair” and 13 “poor” [7]. We could not check funding statements for [1] to [4] from their abstracts.

Regulatory status

• EU: Circadin (2 mg prolonged-release) was authorised on 2007-06-29 for short-term treatment of primary insomnia with poor sleep quality in adults aged 55 or over. The EMA page states it is available only with a prescription (page last updated 2025-07-07) [15].
• UK: The MHRA stated on 2025-08-18 that melatonin is a prescription-only medicine, and that a melatonin product sold as a food supplement must hold a marketing authorisation. The same notice withdrew a children’s gummy that contained 1.5 to 1.7 mg melatonin per gummy without listing it [16]. The emc lists a 3 mg tablet indicated for short-term jet lag in adults, prescription-only (SmPC revised 2025-03-05) [17].
• US: A 2022 CDC report states the FDA regulates melatonin as a dietary supplement, with no prescription needed and lighter oversight than drugs [10]. We did not open an FDA page, so we cite the CDC report for this.
• Germany and individual EU states: not checked. The EU entry above covers only the centrally authorised product.

The label-mismatch problem

Two analyses tested what is in the bottle.

• Erland and Saxena (2017) measured 31 supplements bought in Ontario, Canada. Melatonin ranged from 83% below to 478% above the label, lot-to-lot variation within one product reached 465%, and more than 71% fell outside a 10% margin. Eight products contained serotonin (1 to 75 micrograms) [12]. The sample was Canadian, not US.
• Cohen and colleagues (JAMA, 2023) tested 25 US gummy products. 22 (88%) were inaccurately labelled; measured melatonin was 74% to 347% of the label, from 1.3 mg to 13.1 mg per serving. One product had no detectable melatonin and 31.3 mg of cannabidiol. Only one sample per brand was tested, and tablets and capsules were not assessed. The authors disclosed research support from Consumers Union and PEW Charitable Trusts, and FDA, NIH and USDA grants for a co-author [11].

For anyone reading “high-dose” as a number, these studies matter: the number on a US supplement label may not be what the product contains. The CDC authors note that comparable US quality studies are lacking [10].

Risks and unknowns

• Adult trials: the 2019 review of 37 randomized trials (daily doses 0.15 to 12 mg, most trials 4 weeks or shorter, longest 29 weeks) found few, generally mild effects. Daytime sleepiness was most frequent at 1.66%, then headache and dizziness (0.74% each). It found no life-threatening events, but called long-term evidence scarce [7]. Another review of 50 controlled studies, partly funded by an industry body (Complementary Medicines Australia), saw mostly minor effects, with some endocrine and blood-pressure findings linked to dose and timing and a possible interaction with antihypertensive drugs [8].
• Children and adolescents: a 2023 GRADE review of 22 randomized studies (1,350 patients) found no serious adverse events but more non-serious ones (relative risk 1.56, 95% CI 1.01 to 2.43), and called long-term effects on puberty and bone uncertain. One study suggested possible pubertal delay after more than 7 years [9]. The Cochrane review also flagged case reports of harm in epilepsy and with warfarin [2].
• Accidental ingestion (poison-centre reports, passive and unverified): US poison centres logged 260,435 pediatric melatonin ingestions from 2012 to 2021, a 530% rise in annual cases. Of 27,795 treated in a health facility, 4,097 were hospitalised; five children needed ventilation and two died, though causation was not confirmable [10].
• Heart failure signal (observational, not peer-reviewed): an American Heart Association conference abstract, reported in an AHA release of 2025-11-03, used TriNetX health records of 130,828 adults with chronic insomnia. Heart failure over five years occurred in 4.6% of people with at least a year of recorded melatonin versus 2.7% of matched non-users. The authors cannot show causation. Listed limits: over-the-counter users may sit in the comparison group, doses were not recorded, and insomnia severity and psychiatric conditions were not measured [13]. A 2026 commentary using US NHANES survey data (1999 to 2018) found no significant link between recent melatonin use and prevalent heart failure, and described its own results as hypothesis-generating [14].
• Not studied: long-term randomized safety, repeated large doses in healthy people, and cognitive effects in people without sleep disorders (in the sources we opened).

Verdict on the S-tier claim

Not supported for the claim as posted. Melatonin has real, modest evidence for shifting sleep timing in delayed sleep phase disorder and jet lag [2][4] and small effects on sleep onset [1][3]. The sources we opened do not show cognitive enhancement, the one review that compared ranges found no extra benefit above 5 mg [2], and label testing shows the “dose” in US products is unreliable [11][12]. The “circadian rhythm” entry on the same list is a concept, not a product, and cannot be rated.

Frequently asked questions

Is melatonin a drug or a supplement? It depends on the country. In the EU (Circadin) and the UK it is a prescription medicine [15][16]. In the US the FDA regulates it as a dietary supplement [10]. We did not check Germany separately.

Does a higher dose work better? Not clearly. A cross-trial analysis found larger effects with higher doses and longer trials [1], but the Cochrane jet lag review found nothing gained above 5 mg [2]. Both are comparisons across trials, and we did not check whether any single trial compared dose levels directly.

Do melatonin supplements contain what the label says? Often not. In a 2023 test of 25 US gummies, 22 were inaccurate [11]; a 2017 test of 31 Canadian products found over 71% outside 10% of the label [12].

Is long-term melatonin use linked to heart failure? One unreviewed 2025 observational abstract reported a higher rate, and a 2026 NHANES analysis found no significant association [13][14]. Neither shows cause and effect.

Sources

1. Ferracioli-Oda E, Qawasmi A, Bloch MH, “Meta-analysis: melatonin for the treatment of primary sleep disorders”, PLoS One (2013-05-17). PMID 23691095, read via the Europe PMC record because PubMed blocked automated access. https://pubmed.ncbi.nlm.nih.gov/23691095/
2. Herxheimer A, Petrie KJ, “Melatonin for the prevention and treatment of jet lag”, Cochrane Database of Systematic Reviews (2002). PMID 12076414, read via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/12076414/
3. Auld F et al., “Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders”, Sleep Medicine Reviews (online 2016-07-20; 2017). PMID 28648359; abstract only, effect sizes not read. https://pubmed.ncbi.nlm.nih.gov/28648359/
4. van Geijlswijk IM, Korzilius HP, Smits MG, “The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis”, Sleep (2010-12-01). https://doi.org/10.1093/sleep/33.12.1605
5. Zhdanova IV et al., “Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans”, Sleep (1996-06-01). https://doi.org/10.1093/sleep/19.5.423
6. Weishaupt JH et al., “Reduced oxidative damage in ALS by high-dose enteral melatonin treatment”, Journal of Pineal Research (2006-11). https://doi.org/10.1111/j.1600-079x.2006.00377.x
7. Besag FMC et al., “Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review”, CNS Drugs (2019-12). https://doi.org/10.1007/s40263-019-00680-w
8. Foley HM, Steel AE, “Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence”, Complementary Therapies in Medicine (online 2018-11-03; 2019). https://doi.org/10.1016/j.ctim.2018.11.003
9. Händel MN et al., “The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment”, eClinicalMedicine (2023-07-06). https://doi.org/10.1016/j.eclinm.2023.102083
10. Lelak K et al., “Pediatric Melatonin Ingestions, United States, 2012-2021”, CDC MMWR 71(22) (2022-06-03). https://www.cdc.gov/mmwr/volumes/71/wr/mm7122a1.htm
11. Cohen PA et al., “Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US”, JAMA (2023-04-25). https://jamanetwork.com/journals/jama/fullarticle/2804077
12. Erland LA, Saxena PK, “Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content”, Journal of Clinical Sleep Medicine (2017-02-15). Abstract read via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/27855744/
13. American Heart Association news release on a Scientific Sessions 2025 abstract (Nnadi et al.), reproduced by News-Medical.net (2025-11-03). We could not open the AHA newsroom page or the abstract itself. https://www.news-medical.net/news/20251103/Long-term-use-of-melatonin-supplements-linked-to-higher-risk-of-heart-failure-and-death.aspx
14. Khan B, Lima BB, “Melatonin and cardiovascular risk: an NHANES reality check after recent heart failure concerns”, Open Heart (2026-05-21). https://doi.org/10.1136/openhrt-2026-004108
15. European Medicines Agency, “Circadin” EPAR page (last updated 2025-07-07). https://www.ema.europa.eu/en/medicines/human/EPAR/circadin
16. MHRA via GOV.UK, “Parents and caregivers advised to stop all use of specific brand of kids magnesium gummies due to the presence of an undeclared prescription-only medicine” (2025-08-18). https://www.gov.uk/government/news/parents-and-caregivers-advised-to-stop-all-use-of-specific-brand-of-kids-magnesium-gummies-due-to-the-presence-of-an-undeclared-prescription-only-med
17. Colonis Pharma, “Melatonin 3 mg film-coated tablets, Summary of Product Characteristics”, electronic medicines compendium (emc) (revised 2025-03-05). https://www.medicines.org.uk/emc/product/10405/smpc
18. @dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (2026-10-20); post text read through the fxtwitter mirror, tier placements transcribed from the image by our team. https://x.com/dex7official/status/2112691493261484516

This article is information, not medical advice.